Phase II trial of S-1+oxaliplatin+Cetuximab as first-line treatment in patients with kras-wild type unresectable advanced colorectal cancer - KODK 9
Phase 2
- Conditions
- colorectal cancer
- Registration Number
- JPRN-UMIN000008963
- Lead Sponsor
- Department of Surgery Keio University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Not provided
Exclusion Criteria
1.Severe complications 2.History of severe allergy 3.Peripheral sensory 4.Chickenpox 5.Receiving flucytosine 6.Serious infusion reaction has revealed 7. A case with an acute inflammatory disorder 8. Pregnant or lactating women or women of childbearing potential, and no birth-control 9. Active other malignancies. 10. Brain metastasis 11. Atopic dermatitis 12. Not appropriate for the study at the physician's assessment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method Progression Free Survival,Adverse events,Overall Survival,Relative Dose Intensity